US - Premature Ejaculation (PE) Disorder Therapeutics Market by Route Of Administration, Drug Class and Distribution Channel - Forecast and Analysis 2024-2028

US - Premature Ejaculation (PE) Disorder Therapeutics Market 2024-2028

The US - Premature Ejaculation (PE) Disorder Therapeutics Market size is estimated to grow by USD 478.41 million at a CAGR of 10.22% between 2023 and 2028. 

Demand for topical drug therapies to treat premature ejaculation has a positive impact on market growth. Premature ejaculation remains an underdiagnosed and undertreated disease process, with limited data available on potential underlying mechanisms and long-term outcomes of treatment options. It is among the most common sexual dysfunctions that affect men. Topical therapies, which are commonly used, result in prolonged intravaginal ejaculatory latency time at the expense of potential penile/vaginal hypotheses. Topical medications are considered a first-line treatment option for premature ejaculation, with no specific medication having market approval specifically for the treatment of premature ejaculation. As the topical aerosol has minimal local and negligible systemic side effects, it will likely receive its appropriate regulatory approval for the US - premature ejaculation (PE) disorder therapeutics market. Therefore, the advantages offered by topical therapies are expected to increase their demand, thereby driving the growth of the US premature ejaculation disorder therapeutics market during the forecast period.

Technavio has segmented the market into  route of administration  drug class and distribution channel 

• The route of administration segment is classified into oral and topical
•  The  drug class segment is classified into SSRIs, PDE5 inhibitors, amide anesthetics, and others
• The distribution channel segment is classified into prescription and OTC

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018-2022 besides analyzing the current market scenario.

What will be the size of the US Premature Ejaculation Disorder Market During the Forecast Period?

To learn more about this report, Request Free Sample

US Premature Ejaculation Disorder Market Segmentation by Route Of Administration, Drug Class and Distribution Channel

Route Of Administration Analysis 

Oral

The market share growth by the oral segment will be significant during the forecast period. The significant market share of the oral route segment can be attributed to the popularity and high preference for oral medication as the first line of treatment for premature ejaculation, owing to its ease of use and wide availability. These drugs are available in different forms, such as tablets, capsules, and liquids.

Get a glance at the market contribution of various segments Download PDF Sample

The oral segment was the largest and was valued at USD 374.94 million. The significant market share of the oral route segment can be attributed to the popularity and high preference for oral medication as the first line of treatment for premature ejaculation, owing to its ease of use and wide availability. These drugs are available in different forms, such as tablets, capsules, and liquids. The traditional agents to prolong coitus were alpha amino benzoate and phenoxybenzamine, both of which were associated with severe side effects. Tricyclic antidepressants and, finally, SSRIs were used due to their sustained efficacy on ejaculatory latency and tolerable side effect profile. The mechanism for delayed ejaculation with SSRIs is generally related to the inhibition of various descending pathways linked with the ejaculatory reflex. This is supported by studies that show significant variations in cortical serotonergic function between patients with premature ejaculation in males. Such factors are expected to fuel the segment growth which in turn drives the market growth during the forecast period. 

Route Of Administration Analysis 

SSRIs

SSRIs are a commonly used drug class for premature ejaculation treatment. The drugs can be taken alone or in combination with other drug classes, such as antidepressants. Being the most common drug form for the disease, SSRIs have the largest market share in the US - premature ejaculation (PE) disorder therapeutics market. One of the hypothesized causes of premature ejaculation is abnormal ejaculation caused by disruptions in serotonin control within the central nervous system. According to clinical research, the neurotransmitter serotonin has the biggest influence on the timing of ejaculation. These results led to the use of SSRIs in the treatment of early ejaculation. Moreover, the side effects caused by these drugs are expected to act as a major challenge to the growth of the segment and are expected to hinder the growth of the SSRIs segment of the US premature ejaculation disorder therapeutics market during the forecast period.

PDE5 inhibitors

The lack of approved premature ejaculation drugs in the US by regulatory bodies such as the US Food and Drug Administration (FDA) has propelled the popularity of PDE5 inhibitors, which will drive the US - premature ejaculation disorder therapeutics market. PDE5 inhibitors block the PDE5 enzyme in the smooth muscle cells in the penis, resulting in prolonged erection required for delayed ejaculation. However, these inhibitors do not help in premature ejaculation directly. However, clinical studies show that sildenafil does have several effects, which promote its use in treating premature ejaculation and improving male sexual performance. Vardenafil Vardenafil, a selective inhibitor of cGMP-specific PDE 5, is an oral medication to treat erectile dysfunction in men. It was approved by the US FDA in 2003 for the treatment of erectile dysfunction. The drug has been used regularly as a solution to delay ejaculation required for satisfactory sexual intercourse. The rising demand for PDE5 inhibitors for the treatment of premature ejaculation disorder

Buy Full Report Now

Key US Premature Ejaculation Disorder Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:

Absorption Pharmaceuticals LLC - The company offers premature ejaculation disorder therapeutics such as delay spray, home and away, and threesome.

• Alembic Pharmaceuticals Ltd.
• Amneal Pharmaceuticals Inc.
• Bayer AG, Cipla Ltd.
• Eli Lilly and Co.
• Johnson and Johnson
• Lupin Ltd.
• NeuroHealing Pharmaceuticals Inc.
• Novartis AG
• Pfizer Inc.
• Prinston Pharmaceutical Inc.
• Teva Pharmaceutical Industries Ltd.
• Veru Inc.
• VIVUS LLC
• Aytu BioPharma Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

US Premature Ejaculation Disorder Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. 

Key US Premature Ejaculation Disorder Market Drivers

The high efficacy of off-label drugs leading to high usage by people is notably driving the market growth. There is only one approved product for treating premature ejaculation in the US market. The US - premature ejaculation disorder therapeutics market is dominated by off-label drugs, generic versions of patent-expired drugs, and over-the-counter formulations. The increasing demand for several off-label drugs is a primary factor driving the growth of the market. The US - premature ejaculation (PE) disorder therapeutics market has witnessed an increased use of off-label drugs of different drug classes, such as SSRIs and PDE5 inhibitors, due to their effectiveness in the treatment of premature ejaculation. The treatment with off-label drugs belonging to SSRIs and PDE5 inhibitors has revolutionized the treatment approach. Further, PDE5 inhibitors are the gold-standard first treatment for men with erectile dysfunction. Many of the clinical studies recommend that the use of PDE5 inhibitors can be useful in premature ejaculation disorder treatment.

Moreover, regardless of the mechanism of PDE5 inhibitors, they are considered to be safe and effective as a therapeutic adjunct for premature ejaculation in men. Therefore, they are highly used as off-label drugs for the treatment of premature ejaculation. The high efficacy of these drugs increases their demand among end-users, thereby contributing to the US - premature ejaculation disorder therapeutics market growth. Therefore, the high efficacy of off-label drugs leading to high usage by end-users will drive the growth of the US premature ejaculation disorder therapeutics market during the forecast period.

Significant US Premature Ejaculation Disorder Market Trends

The use of nanotechnology in drug delivery is an emerging trend shaping the market growth.  Nanotechnology was first introduced in the 1980s. Since then, it has provided researchers with new approaches to develop drug delivery systems for various diseases. Many - novel technologies associated with nanotechnology have been brought into clinical use in the past ten years, and countless patients have benefited from them, which convinces the researchers of the bright prospect of nanotechnology in the field of medicine. PDE-5 inhibitors, including tadalafil, sildenafil, and vardenafil, are widely used as off-label drugs for the treatment of premature ejaculation, owing to their ability to bind and inhibit the PDE-5 isoenzyme competitively. All of the currently used PDE-5 are orally administered. Moreover, they have poor aqueous solubility, which results in low bioavailability and systemic side effects, such as facial flushing, headache, nasal congestion, and dyspepsia. Similarly, dapoxetine, a kind of SSRI, can reach a peak in serum concentration in a short period.

However, with the application of nanotechnology, researchers have explored new approaches to medicine delivery to promote efficacy and minimize the side effects of the currently available agents for premature ejaculation. For example, a study conducted by Han et al. demonstrated that nanoparticles represent a potential novel route for topical delivery of erectogenic agents, which could improve the safety profile of the existing orally administered drugs by avoiding the effects of absorption and first-pass metabolism and would be less hazardous than injection. Therefore, nanotechnology has provided researchers with new approaches to developing drug delivery systems, which is expected to contribute to the growth of the US premature ejaculation disorder therapeutics market during the forecast period.

Major US Premature Ejaculation Disorder Market Challenges

The availability of alternative treatment options is a significant challenge hindering market growth. While the market has only one approved product, the growing number of premature ejaculation cases globally has led to an increase in the number of alternative treatment methods for the disease. Some of the alternate treatment methods are counseling, homeopathy, psychotherapy, yoga, and herbal therapy. There are also other natural premature ejaculation treatment options, such as ginseng tea or supplements, raw almond milk, and Ayurvedic options. Psychotherapy and various behavioral therapies are used to treat premature ejaculation. Psychological therapy requires strong compliance from the partner and is time-consuming, expensive, and less effective than pharmacotherapy, and its efficiency decreases with time. 

In addition, the growing popularity of alternative premature ejaculation treatment options has resulted in the diminished growth of authentic pharmacological therapies offered by various pharmaceutical companies, thus posing a threat to the US - premature ejaculation (PE) disorder therapeutics market growth. Therefore, the availability of alternative treatment options will hinder the growth of the US premature ejaculation disorder therapeutics market during the forecast period.

Buy Now Full Report

Key US Premature Ejaculation Disorder Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

US Premature Ejaculation Disorder Market Customer Landscape

Segment Overview

The US Premature Ejaculation Disorder Market report forecasts market growth by revenue and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

• Route Of Administration Outlook
  • Oral
  • Topical

• Drug Class Outlook
  • SSRIs
  • PDE5 inhibitors
  • Amide anesthetics
  • Others

• Distribution Channel Outlook
  • Prescription
  • OTC

US Premature Ejaculation Disorder Market Scope
Report Coverage	Details
Page number	152
Base year	2023
Historic period	2018-2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 10.22%
Market Growth 2024-2028	USD 478.41 million
Market structure	Concentrated
YoY growth 2023-2024(%)	10.1
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	Absorption Pharmaceuticals LLC, Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Bayer AG, Cipla Ltd., Eli Lilly and Co., Johnson and Johnson, Lupin Ltd., NeuroHealing Pharmaceuticals Inc., Novartis AG, Pfizer Inc., Prinston Pharmaceutical Inc., Teva Pharmaceutical Industries Ltd., Veru Inc., VIVUS LLC, Aytu BioPharma Inc., Royalty Pharma plc, and Sebela Pharmaceuticals Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this US Premature Ejaculation Disorder Market in Country Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the US premature ejaculation disorder market between 2024 and 2028
• Precise estimation of the US Premature Ejaculation Disorder Market size and its contribution to the market in focus on the parent market
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on companies' position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market across the US
• A thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of US Premature Ejaculation Disorder Market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch